Nanologica is a nanotechnology company developing nanoporous silica particles for applications within life science. This competency is applied in two business areas – drug development and chromatography, a separation technique used in drug development and drug production. The Company’s mission is to contribute to providing better and cheaper treatments for patients worldwide, through the technology platform NLAB Silica™.

Scroll back to top

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings ACCEPT

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Presentations

Read more:

Categories

Archive per year

Investerarlunch hos Erik Penser Bank, 26 juni

Vd Andreas Bhagwani kommenterar dagens pressmeddelande gällande uppdragsavtal med Vicore Pharma

Vd Andreas Bhagwani kommenterar Nanologicas årsstämma 2020

Vd Andreas Bhagwani kommenterar Nanologicas riktade emission 26 maj 2020

Vd Andreas Bhagwani presenterar delårsrapport för första kvartalet 2020

Presentation från Biosimilar/Drug Delivery Seminar – 16 april